The AmpliChip ® CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism
- 9 July 2012
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 16 (8) , 897-903
Abstract
Aim: Genetic factors can result in variance in drug metabolism enzyme function, which is one major mechanism impacting on interindividual variability in response and side effects. We therefore performed a pilot study to investigate genetic variants in the drug metabolizing enzymes CYP2D6 and CYP2C19. Methods: We evaluated 35 schizophrenic and 39 obsessive compulsive disorder (OCD) patients treated with various antipsychotics and antidepressants. Patients were assessed for treatment response and side effects. Genotyping for CYP2D6 and CYP2C19 was performed using the AmpliChip ® . Statistical analysis was performed using analysis of variance and Fisher's exact test. Cases of poor metabolizers (PMs) or ultrarapid metabolizers (UMs) were examined in further detail to assess medication outcomes. Results: Statistical analysis identified no overall significant association of CYP2D6 metabolizer status with treatment response or occurrence of side effects. Nonetheless, case reports of PM and UM individuals indicated lack of response and/or occurrence of side effects in most of these patients. A secondary analysis comparing OCD subjects with impaired 2D6 function to extensive metabolizers was significant ( p =0.021). Conclusion: Although not conclusive, there was some association between CYP2D6 impaired metabolic status and medication response. Our case reports suggest a potential clinical benefit of CYP genotyping for specific patients. Further validation of CYP2D6 and CYP2C19 testing in prospective, randomized trials is warranted.Keywords
This publication has 55 references indexed in Scilit:
- The Potential of GenotypingScience, 2008
- CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC‐INDUCED EXTRAPYRAMIDAL SIDE‐EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPYClinical and Experimental Pharmacology and Physiology, 2008
- The Crucial Role of the Therapeutic Window in Understanding the Clinical Relevance of the Poor Versus the Ultrarapid Metabolizer Phenotypes in Subjects Taking Drugs Metabolized by CYP2D6 or CYP2C19Journal of Clinical Psychopharmacology, 2007
- Epileptiform Seizure After Sertraline Treatment in an Adolescent Experiencing Obsessive-Compulsive Disorder and Presenting a Rare Pharmacogenetic StatusJournal of Clinical Psychopharmacology, 2006
- The AmpliChip™ CYP450 Genotyping TestMolecular Diagnosis & Therapy, 2006
- Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19Psychosomatics, 2006
- The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatmentClinical Pharmacology & Therapeutics, 2002
- Pharmacogenomics in schizophrenia: the quest for individualized therapyHuman Molecular Genetics, 2002
- A Pilot Study on Risperidone MetabolismThe Journal of Clinical Psychiatry, 1999
- Cytochrome P4502D6 genotype does not determine response to clozapine.British Journal of Clinical Pharmacology, 1995